Oragenics Bolsters Executive Team by Appointing Janet Huffman as CFO

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company committed to combating infectious diseases such as COVID-19, is thrilled to welcome Janet Huffman as Chief Financial Officer. Ms. Huffman boasts an impressive résumé with over a decade of financial executive leadership experience in publicly traded and private healthcare organizations. We are confident her expertise and comprehensive skill set will be invaluable as we continue our mission to fight infectious diseases.

Oragenics is thrilled to welcome Janet to the team as the company’s CFO. With her extensive background in the public company sector, her expertise in raising capital and M&A transactions, and her knowledge of the healthcare market, Janet is the perfect addition to propel Oragenics forward with its development plans. Her strategic results and strong understanding of the healthcare industry will be a great asset to the team, and Oragenics is excited to benefit from her experience and guidance.

Ms. Huffman is an experienced Chief Financial Officer with an impressive career. Most recently, she was CFO of TRxADE HEALTH, Inc., a Nasdaq-listed company focused on health services IT for retail pharmacies. In 2019, she was a founding member of Banyan Pediatric Care Centers and served as its CFO until its merger with Assisted 4 Living, Inc. in 2021. She then continued her role as CFO until February 2022. Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company. She has also held positions with Family Home Health Services, Infinity Homecare and Regional Director of Operations.

I am thrilled to join Oragenics as Chief Financial Officer and work alongside Kim and the rest of the team to build relationships with the financial community and secure the funding necessary to advance our product pipeline. My expertise in financial execution and commitment to responsible cash management will be vital in helping the company to realize its development strategy and achieve success. I am passionate about Oragenics’ dedication to combatting infectious diseases, and am excited to optimize our financial path to maximize benefits for all stakeholders.

Ms. Huffman furthered her education by earning both a Bachelor’s and Master’s degree in accounting from the University of South Florida. Having achieved this milestone, she continues to demonstrate her dedication to her chosen field and uphold a high standard of excellence.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage company on a mission to fight infectious diseases, such as COVID-19 and its variants, as well as multi-drug resistant organisms. Its leading product, NT-CoV2-1, is an intranasal vaccine candidate that has been designed using spike protein research from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) to reduce viral transmission, and provide a more convenient form of administration. Additionally, the company has a lantibiotics program that features a novel class of antibiotics to combat bacteria that have become resistant to existing commercial antibiotics.

Leave a Comment